Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitiglinide + voglibose
- Development stage
- Unknown
- Lead developer
- Kissei Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**GLUBES** is an oral fixed-dose antidiabetic combination of mitiglinide calcium hydrate and voglibose, developed and marketed in Japan by Kissei for type 2 diabetes mellitus when concomitant treatment with both components is appropriate. Each tablet contains mitiglinide calcium hydrate 10 mg and voglibose 0.2 mg. Mitiglinide is a rapid, short-acting insulin secretagogue that promotes early postprandial insulin release, while voglibose inhibits intestinal alpha-glucosidases to delay carbohydrate digestion and absorption, thereby reducing postprandial glucose excursions. GLUBES was launched as a conventional tablet in July 2011; an orally disintegrating tablet formulation was launched in June 2019. ([kissei.co.jp](https://www.kissei.co.jp/e_contents/news/2011/20110721-668.html))
- Brand names
- GLUBESGLUBES Combination OD TabletGLUBES Combination Tablet
- Other names
- mitiglinide calcium hydrate + voglibosemitiglinide calcium hydrate/voglibose
02
Targets
ATP-sensitive potassium channel complex (Kir6.2/SUR1)Sucrase-Isomaltase
Beyond the preview
Go deeper on mitiglinide + voglibose.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitiglinide + voglibose.